JAK1 and beyond. Investor Presentation January Copyright 2014 Galapagos NV
|
|
- Toby Lewis
- 8 years ago
- Views:
Transcription
1 JAK1 and beyond Investor Presentation January 2014 Copyright 2014 Galapagos NV
2 Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for your information. This presentation may contain forward-looking statements, including, without limitation, statements containing the words believes, anticipates, expects, intends, plans, seeks, estimates, may, will and continues as well as similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the audience is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as at the date of this presentation. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this presentation to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation. Neither Galapagos nor any of its officers, employees, advisers, or agents makes any representation or warranty, express or implied, as to any matter or as to the truth, accuracy, or completeness of any statement made in this presentation, made in conjunction therewith or in any accompanying materials or made at any time, orally or otherwise, in connection with the matters referred to herein and all liability in respect of any such matter or statements is expressly excluded. 2
3 Galapagos at a glance Pipeline of novel mode of action medicines five Phase 2 studies with JAK1 in five disease areas (3 GSK-led) two new modes of action in Phase 1 and 2, six candidates, 20 in discovery Major alliances with AbbVie, JnJ, GSK, Servier Leading fee-for-service provider with BioFocus & Argenta 800 staff, research sites in 5 countries, HQ in Belgium Market cap ~ 515 M, 29.7 M shares Ticker symbol 3
4 Growth strategy Execute development of JAK1 Phase 2 programs in RA & Crohn s Build mature clinical portfolio partnered and proprietary Continue productive pharma alliances Sign new alliances and partnerships to leverage our technology Grow Service division revenues 4
5 Revenue generating business model New mode-of-action medicine platform Fee-for-service Alliance business Licensing 5
6 Service division strong in top segment $600 M premium services market Target identification & validation Assay development Screening Lead optimization Preclinical testing Ph I, II, III clinical trials Galapagos service division AMRI WuXi Evotec Galapagos services competitive strengths: scientific excellence discovery of novel targets in human primary cells large, integrated deals with high renewal & expansion rate firewalled sites allow for different clients on same target 6
7 Pharma alliances Indication Partner Deal value Year Inflammation 219 M + royalties 2006 Inflammation 1 B + royalties 2007 Osteoarthritis 300 M + US rights + royalties 2010 Oncology 260 M + US rights + royalties 2011 Autoimmune $1.4 B + double-digit royalties 2012 Cystic fibrosis $405 M + double-digit royalties, cofunding 2013 Alliances have brought in > 390 M in cash since 2006 Source of promising molecules and targets for GLPG 7
8 Deal structure on GLPG0634 Upfront payment $150 M, $20 M expansion payment Galapagos performs & funds Phase 2 in RA & Crohn s License fee $200 million after RA Phase 2B, $50 M Crohn s success fee AbbVie performs & funds Phase 3, registration & commercialization GLPG to receive up to $1 B in milestones + double digit royalties Tax benefits from Belgian Patent Income Deduction law Phase 2 Phase 3 Marketing and sales handover after RA Phase 2B Benelux 8
9 Deal structure on CF Both companies contribute funding & science AbbVie commercializes, GLPG retains China/South-Korea, co-promotion rights in Benelux Upfront payment $45 M GLPG to receive up to an additional $360 M in future milestones + double digit royalties Tax benefits from Belgian Patent Income Deduction Law Discovery Preclinical Phase 2 Phase 3 Marketing & sales Pending achievement of pre-determined criteria 9
10 Broad and deep (pre)clinical pipeline Licensing Indications Partner Target Lead program Stage RA/Crohn s AbbVie JAK1 634 Phase 2B Lupus/Psoriasis/UC Licensed to GSK JAK1 GSK Phase 2 Ulcerative colitis FFA2 974 Phase 2 Inflammatory bowel disease JnJ novel 1205 Phase 1 MRSA DNA pol IIIα 1492 Inflammation JnJ novel Inflammation GSK novel 6 candidates Oncology novel 1790 Cystic Fibrosis AbbVie/GLPG novel 1837 In addition, >20 programs in discovery phase 10
11 JAKs in inflammation, Phase 2+ Company Drug JAK profile Indications Phase Pfizer Xeljanz JAK3>JAK1>JAK2 Incyte/Lilly baricitinib JAK1=JAK2 RA, JIA, PA, psoriasis, UC, AS RA, diabetic kidney disease Approved in US Phase 3 Vertex VX-509 JAK3 RA Phase 2 GLPG/AbbVie 634 JAK1 RA, Crohn s Phase 2B GSK GSK JAK1 SLE, psoriasis, UC Phase 2 Astellas/JnJ ASP015K JAK3/JAK1 RA Phase 2 AbbVie ABT-494 JAK1 RA Phase 2 GLPG has most advanced JAK1 selective compound 11
12 GLPG0634 The first selective JAK1 inhibitor JAK1 inhibition is an accepted new MOA for autoimmune 634 is most advanced JAK1 compound for RA and IBD expected launch in 2017/2018 timeframe high level of efficacy in two independent 4-week RA studies no efficacy gain observed beyond 200 mg 634 is only JAK inhibitor to show: efficacy in RA without impact to LDL, ALT/AST, hemoglobin 24/7 target inhibition after QD dosing 634 profile unmatched by other JAKs in autoimmune 12
13 Pooled results PoC and Phase 2A Moderate to severe RA patients CRP (mg/l) - change from baseline DAS28 - % change from baseline 30 Pbo1 Pbo2 30mg 75mg 150mg 200mg 300mg 0 Pbo1 Pbo2 30mg 75mg 150mg 200mg 300mg ** * ** ** ** ** Full dose range including 200 mg QD from Proof of Concept study Dose trend in efficacy with similar effect for doses >75mg No safety findings 13
14 634 Phase 2B program in RA Moderate to severe RA patients with inadequate MTX response Add-on to MTX 595 patients Monotherapy 280 patients Long term extension 14
15 634 in Crohn s Disease Crohn s market by : $4.5 billion Galapagos funds and runs Ph 2, AbbVie pays $50 M success fee 1 st selective JAK1 inhibitor in Ph 2 in Crohn s 20-week Phase 2A/B study in 180 patients, measuring: induction of disease remission early maintenance of its beneficial effects Timeline: start early 2014, read out topline results in Q enables direct move into Ph 3, gains 2 years in Crohn s ¹ Source: Decision Resources
16 Expected timelines st patient in Crohn s Last RA patient at 12 wk analysis Topline 24 wk RA studies AbbVie licensing decision Last RA patient in Topline 12 wk RA studies Topline Crohn s study Presentations at major conferences 16
17 GSK Ph2 studies with GSK GSK (previously GLPG0778) is an investigational selective JAK1 inhibitor inlicensed by GSK from GLPG in Feb 2012 GSK runs and funds further research, no cost to Galapagos In Phase 2 in three indications, expected completion: psoriasis: March 2014 ulcerative colitis: November 2014 lupus: November 2015 Galapagos milestone payment upon successful POC 17
18 974 Inhibits novel target in inflammatory disease 974 is a potent & selective antagonist of FFA2 reduces migration of neutrophils, major issue in ulcerative colitis first inhibitor of FFA2 to be evaluated clinically no animal models available 974 is fully proprietary to Galapagos 18
19 974 Results Ph1 multiple ascending dose study Pharmacodynamics (Day 13) Acetate-induced CD11b up regulation 100 % inhibition vs predose D Time after last dosing (h) 32 healthy volunteers, 4 cohorts, per cohort 6 active & 2 placebo 24 h inhibition at 200 mg BID Source: Company internal data 19
20 974 Ph2 PoC ulcerative colitis Disease of the colon characterized by ulcers Phase 2: 45 patients, 4 week dosing, 200 mg BID vs placebo 16 centers in 4 European countries evaluate safety & tolerability, characterize PK explore efficacy & effects on selected biomarkers Phase 2 PoC results expected H
21 Anti-bacterial platform Target: DnaE, a subunit of DNApolIII key enzyme involved in bacterial DNA replication (Gram + and Gram -) bactericidal one bug one drug paradigm, in combination with fast diagnosis Unique, scalable discovery platform to target different bacteria tripartite crystal structure: key asset for rational drug design unique natural product family drugs selected for S. aureus and C. difficile discovery programs targeting ESKAPE species 21
22 1492, our MRSA program Methicillin-Resistant Staphylococcus Aureus: resistant to most antibiotics spreading outside hospitals urgent medical need and high demand from clinicians 1492 offers new approach to treat MRSA active against all S. aureus strains excellent in vivo activity p.o., s.c., i.v. no cross resistance with existing antibiotics inhibits 280/280 S. aureus strains tested, of which 163 MRSA 22
23 Tripartite mode of action X-ray structure DNA primer DNA template 1492 DnaE 1492 binds at interface between polymerase, DNA template and primer 23 Resolution: 2.8Å
24 S. aureus infection mouse model 1492 dose response Thigh infection S. aureus CFU/thigh 1.00E E E E E+02 *** T1h T24h 50 mg/kg Cipro SC 50 mg/kg SC 50 mg/kg Line SC 50 mg/kg SC 5 GLPG1492 mg/kg SC 5 mg/kg SC 15 GLPG1492 mg/kg SC 15 mg/kg SC 50 GLPG1492 mg/kg SC 50 mg/kg SC 120 GLPG1492 mg/kg SC 120 mg/kg Administration s.c. BID, PI = Post infection SC Treatment T1-T7 PI, Sacrifice T24 PI *:p<0,05 **:p<0,01 ***:p<0.001 *** *** placebo Cipro Line 1492 *** Efficacy demonstrated in dose-dependent manner from 15 mg/kg 24
25 Timelines CF Delivery PCC potentiator GLPG1837 GLPG starts Phase 1 potentiator GLPG1837 GLPG starts Phase 2 potentiator GLPG Deal with AbbVie in CF Delivery PCC corrector GLPG starts Phase 1 corrector 70,000 patients worldwide; 1,000 new CF cases diagnosed each year Median age of survival is in the late 30 s Combination therapy needed for largest mutation F508del, 70% of patients 25
26 Clinical planning 2014 H1 H RA Phase 2B fully recruited RA Start Darwin Crohn s Start Phase UC Phase 2 topline results JnJ Start Phase anti-bacterial Start Phase RA Phase 2B 12-w topline results Crohn s Phase 2 fully recruited GSK psoriasis Phase 2 results IBD - JnJ Start Phase CF Start Phase 1 26
27 Bright outlook for Galapagos Leadership in JAK1 space: two compounds (one licensed to GSK) in Phase 2 in five indications AbbVie deals & out-licensing to GSK highlight success of our approach Broad pipeline provides further opportunities for clinical success both in internal and alliance programs Business model supports investment in promising proprietary programs Galapagos in excellent position to build on its R&D strengths 27
JAK1 and beyond. Investor Presentation February 2013. Copyright 2013 Galapagos NV
JAK1 and beyond Investor Presentation February 2013 Copyright 2013 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for your information.
More informationWeek 12 study results
Week 12 study results 15 April 2015 Copyright 2015 Galapagos NV Disclaimer This document may contain certain statements, including forward-looking statements, such as statements concerning the safety and
More informationA career on the science park
A career on the science park Onno van de Stolpe December 2014 Copyright 2014 Galapagos NV 1987 MOGEN Agricultural biotech pioneer Design of transgenic plants with improved traits Close link with Prof Schilperoort
More informationGalapagos reports largest cash balance ever
Regulated information 3 March 2016, 22.00 CET Galapagos reports largest cash balance ever Key 2015 financials: Cash burn of 122 million, in line with guidance Cash balance on 31 December 2015 of 348 million
More informationR&D Update 2014. Onno van de Stolpe, CEO Piet Wigerinck, CSO. New York City, 17 June 2014. Copyright 2014 Galapagos NV
R&D Update 2014 Onno van de Stolpe, CEO Piet Wigerinck, CSO New York City, 17 June 2014 Copyright 2014 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by
More informationA transition and execution year for Galapagos. Annual Report 2014
A transition and execution year for Galapagos Annual Report 2014 CONTENTS Contents 1 The Galapagos Group Letter from the CEO... 4 At a glance... 6 Strategy... 8 Overview of Galapagos NV... 9 Going concern
More informationA transition and execution year for Galapagos. Annual Report 2014
A transition and execution year for Galapagos Annual Report 2014 CONTENTS Contents 1 The Galapagos Group Letter from the CEO... 4 At a glance... 6 Strategy... 8 Overview of Galapagos NV... 9 Going concern
More informationREPORT OF THE BOARD OF DIRECTORS 4 AUDITED CONSOLIDATED 2013 ANNUAL FINANCIAL STATEMENTS 31
AnnualReport 2013 Table of contents REPORT OF THE BOARD OF DIRECTORS 4 AUDITED CONSOLIDATED 2013 ANNUAL FINANCIAL STATEMENTS 31 CONSOLIDATED INCOME STATEMENTS AND CONSOLIDATED STATEMENT OF COMPREHENSIVE
More informationAdmission to listing and trading on Euronext Brussels and Euronext Amsterdam of new ordinary shares in Galapagos NV
(a public company with limited liability (naamloze vennootschap/société anonyme) organized and existing under the laws of Belgium, with its corporate seat in Mechelen, Belgium) Admission to listing and
More informationNew Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
More informationEVT Execute & EVT Innovate Leading drug discovery
EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking
More informationNovel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation
Novel Targeted Immunotherapy Approach for Metastatic Melanoma Under Phase 3 Investigation Hans S. Keirstead President, NeoStem Oncology NeoStem Presented by GTC, a conference production company 626-256-6405
More informationCompany Presentation June 2011 Biotest AG 0
Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and
More informationEVT Execute & EVT Innovate World-class drug discovery
EVT Execute & EVT Innovate World-class drug discovery Evotec AG, First Quarter Report 2015, 12 May 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements,
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September
More informationCAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationDaiichi Sankyo to Acquire Ambit Biosciences
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationBuilding innovative drug discovery alliances. Profitable. Growth Go
Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains
More informationEigenkapitalforum 2013. Company Update November 12, 2013
Eigenkapitalforum 2013 Company Update November 12, 2013 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationVERTEX PHARMACEUTICALS INC / MA
VERTEX PHARMACEUTICALS INC / MA FORM 8-K (Unscheduled Material Events) Filed 6/1/2005 For Period Ending 5/31/2005 Address 130 WAVERLY STREET CAMBRIDGE, Massachusetts 02139-4242 Telephone 616-577-6000 CIK
More informationQ3 2015 Conference Call
November 4, 2015 Q3 2015 Conference Call 1 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationAcucela Inc. IR Meeting
Acucela Inc. IR Meeting Tokyo May 20, 2015 Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening
More informationH1 2013 Innovation. efficiency
H1 2013 Innovation efficiency on track Evotec AG, H1 2013 Interim Report, 08 August 2013 Forward-looking statements Information set forth in this presentation contains forward-looking statements, which
More informationRodman & Renshaw Annual Global Investment Conference. September 13, 2010
Rodman & Renshaw Annual Global Investment Conference September 13, 2010 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in
More informationCompany Update. March 2011
Company Update March 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various
More informationAntares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul
Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS Paul Antares Mission: To develop and commercialize self-administered parenteral medicines
More informationTERM SHEET EXAMPLE. 1 P age
1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with
More informationTheravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update
August 10, 2015 Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update DUBLIN, IRELAND -- (Marketwired) -- 08/10/15 -- Theravance Biopharma, Inc. (NASDAQ:
More informationCrohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals. Sponsored Research Program in Inflammatory Bowel Disease
Crohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals Sponsored Research Program in Inflammatory Bowel Disease Presentation Overview Background on inflammatory bowel disease Partner Overview
More informationStrategic Consulting Services
Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief
More informationAdaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -
Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011
More informationREFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,
More informationProbiotics for the Treatment of Adult Gastrointestinal Disorders
Probiotics for the Treatment of Adult Gastrointestinal Disorders Darren M. Brenner, M.D. Division of Gastroenterology Northwestern University, Feinberg School of Medicine Chicago, Illinois What are Probiotics?
More informationBNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
More informationMid-Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) Mid-Clinical Stage Antiviral Drug Development Company Investor Update 20 August 2015 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au
More informationMedical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
More informationBreakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014
Oramed Pharmaceuticals, Inc. Initiating Report Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014 Key data Sector Rating Biotechnology BUY Target Price $45.00
More informationJAK inhibitors in Rheumatoid Arthritis - A Cross-Trial Competitor Analysis
JAK inhibitors in Rheumatoid Arthritis - A Cross-Trial Competitor Analysis (12-week EFFICACY with background DMARD) Galapagos/Abbvie Filgotinib Pfizer - Tofacitinib Incyte/Eli Lilly Baricitinib Vertex-
More informationKempen & Co 4 th Healthcare/Life Sciences Conference. Brussels March 29, 2011
Kempen & Co 4 th Healthcare/Life Sciences Conference Brussels March 29, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included
More informationBuilding innovative drug discovery alliances. Addressing causes not. symptoms in diabetes
Building innovative drug discovery alliances Addressing causes not symptoms in diabetes Evotec AG, Analyst information on CureBeta Alliance with Janssen, Hamburg, 2012 Forward-looking statements Information
More informationThe Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010
The Ultimate Healthcare & Biotechnology Event in 2010 Deborah Rathjen CEO & Managing Director 24 March 2010 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"
More informationUPDATED INVESTOR PRESENTATION June 2015
UPDATED INVESTOR PRESENTATION June 2015 Forward-looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationAugust 28, 2012. Company Update Commerzbank Sector Conference Week
August 28, 2012 Company Update Commerzbank Sector Conference Week Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationImmunovaccine Inc. (TSX-V: IMV) July 2011
Immunovaccine Inc. (TSX-V: IMV) July 2011 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities
More informationValneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013
Valneva Reports Preliminary FY 2013 Revenues of EUR 36.0m and Cash Position of EUR 40.2m at End of 2013 Revenue Ahead of Guidance and Cash Target Met in First year Following Merger Total revenues and grants
More informationDec. 9, 2013, 11:00 a.m. EST
Dec. 9, 2013, 11:00 a.m. EST Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban)
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationTherapeutic Class Overview : Psoriasis Plaque Psoriasis & Psoriatic Arthritis - Novel Oral Drugs And Biologics To Change Future Treatment Paradigm
Brochure More information from http://www.researchandmarkets.com/reports/2763286/ Therapeutic Class Overview : Psoriasis Plaque Psoriasis & Psoriatic Arthritis - Novel Oral Drugs And Biologics To Change
More informationCommerzbank Sector Conference Week. Company Update August 27, 2013
Commerzbank Sector Conference Week Company Update August 27, 2013 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationBiotech Short Profile
The Company X is leading the development of next generation biological therapies and production systems. The Company is in two pivotal Phase III clinical studies in colorectal cancer for a unique anticancer
More informationSpinning out in the UK personal experiences and perspectives
Professor Neil A. Williams Head of Department of Cellular and Molecular Medicine Founder, Director of Science, KWS BioTest Ltd Founder, Aegis (Hunter-Fleming) Pharmaceuticals Ltd Spinning out in the UK
More information9. WestLB Deutschland Conference. Frankfurt November 16, 2011
9. WestLB Deutschland Conference Frankfurt November 16, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationNasdaqGS: SNTS. September 5, 2012
NasdaqGS: SNTS September 5, 2012 Safe Harbor This presentation may include forward-looking statements that are based on management s beliefs and assumptions and on information currently available to management.
More informationTo Our Shareholders. 2013: Keeping Our Commitments, Continuing Our Momentum. Continued Transformation of Our Innovative Core. Annual Review 2013
To Our Shareholders In 2013, Pfizer achieved solid results for patients, consumers, and shareholders by maintaining our focus on developing new therapies, driving growth, and delivering value. Ian C. Read
More informationVERTEX PHARMACEUTICALS INC / MA
VERTEX PHARMACEUTICALS INC / MA FORM 10-K (Annual Report) Filed 03/01/13 for the Period Ending 12/31/12 Address 130 WAVERLY STREET CAMBRIDGE, MA 02139-4242 Telephone 6173416100 CIK 0000875320 Symbol VRTX
More informationPaul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS
Paul K. Wotton, Ph.D President and Chief Executive Officer May 2012 AMEX: AIS Safe Harbor Statement This presentation may contain forward-looking statements which are made pursuant to the safe harbor provisions
More informationLocalised Cancer Treatment. PCI Biotech. Amphinex a new product for localised cancer treatment
Localised Cancer Treatment PCI Biotech Amphinex a new product for localised cancer treatment Disclaimer This document (the Presentation ) has been produced by PCI Biotech Holding ASA (the Company ). The
More informationOREXO AB SPECIALTY PHARMA FOCUSING ON OPIOID DEPENDENCE AND PAIN TREATMENT NORDIC LIFE SCIENCE CONFERENCE
OREXO AB SPECIALTY PHARMA FOCUSING ON OPIOID DEPENDENCE AND PAIN TREATMENT NORDIC LIFE SCIENCE CONFERENCE NASDAQ STOCKHOLM: ORX US OTC MARKET: ORXOY (ADR) APRIL 27 TH, 2015 LEGAL DISCLAIMER This presentation,
More informationCompany Profile // May 2012
Company Profile // May 2012 1 Disclaimer This presentation has been prepared for the group of companies held by Clal Biotechnology Industries Ltd. (CBI or the Group ) and is provided to you solely for
More informationANTARES PHARMA. Paul K. Wotton Ph.D. President and Chief Executive Officer. Jefferies 2014 Global Healthcare Conference Wednesday June 4, 2014
ANTARES PHARMA Paul K. Wotton Ph.D. President and Chief Executive Officer Jefferies 2014 Global Healthcare Conference Wednesday June 4, 2014 NASDAQ:ATRS 1 Safe Harbor Statement This presentation may contain
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationCommerzbank Sector Conference. Frankfurt August 30, 2011
Commerzbank Sector Conference Frankfurt August 30, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationMicromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -
A Microbiology Services Company Lab Services Research - Consulting - Regulatory Company description is a microbiology services company specializing in antiinfective discovery and development for the pharmaceutical,
More informationGene Silencing Oligos (GSOs) Third Generation Antisense
Gene Silencing Oligos (GSOs) Third Generation Antisense Walter R. Strapps, Ph.D. Executive Director, RNA Therapeutics Idera Pharmaceuticals Cambridge, MA NASDAQ: IDRA www.iderapharma.com Idera is a leader
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationVERTEX PHARMACEUTICALS INC / MA
VERTEX PHARMACEUTICALS INC / MA FORM 10-K (Annual Report) Filed 02/19/10 for the Period Ending 12/31/09 Address 130 WAVERLY STREET CAMBRIDGE, MA 02139-4242 Telephone 6165776000 CIK 0000875320 Symbol VRTX
More informationInnovation Efficiency Evotec Company Overview. Evotec AG, Company presentation, Jefferies 2015 Global Healthcare Conference, 04 June 2015, New York
Innovation Efficiency Evotec Company Overview Evotec AG, Company presentation, Jefferies 2015 Global Healthcare Conference, 04 June 2015, New York Forward-looking statements Information set forth in this
More informationPROMETIC LIFE SCIENCES INC.
PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.
More informationMedivir s financial reports are available from its Website, www.medivir.se from these dates, under the Financial Information heading.
PRESS RELEASE, 23 October INTERIM REPORT, 1 January - 30 September In July, Medivir entered a licensing agreement with Boehringer Ingelheim (BI) on MIV-310. CCS group divested to the Segulah II L.P. investment
More informationEVT Execute & EVT Innovate Innovation Efficiency
EVT Execute & EVT Innovate Innovation Efficiency Evotec AG, H1 2015 Interim Report, 12 August 2015 Forward-looking statements Information set forth in this presentation contains forward-looking statements,
More informationINTERIM REPORT, 1 January - 30 June 2003
PRESS RELEASE, 9 July INTERIM REPORT, 1 January - 30 June In May, Medivir reached a licensing agreement on MIV-210 with GlaxoSmithKline; EUR 6 m was received upon signing and up to EUR 86 m on the achievement
More informationEpizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update
Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update Initiated pediatric MLL-r Phase 1b dose escalation study of DOT1L inhibitor EPZ-5676 in May 2014; three proof-of-concept
More informationTuberculosis OUR MISSION THE OPPORTUNITY
Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is
More informationUlcerative colitis Pipeline Highlights - 2015
Brochure More information from http://www.researchandmarkets.com/reports/3031128/ Ulcerative colitis Pipeline Highlights - 2015 Description: The latest report Ulcerative colitis Pipeline Highlights 2015
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationFirst Quarter 2015 Earnings Teleconference. April 28, 2015
First Quarter 2015 Earnings Teleconference April 28, 2015 Introduction Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements and Non-GAAP Financial Information Our discussions
More informationQuarterly Shareholder Update December 2015
Quarterly Shareholder Update December 2015 Pharmaxis an emerging powerhouse in drug development Dear Shareholder, Pharmaxis commenced the December 2015 quarter with the foundations for future value firmly
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationImproving Life Transforming Value. May 1 st, 2015
Improving Life Transforming Value May 1 st, 2015 Forward Looking Statement This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationH1 2014 Strong Execution for more Innovation
H1 2014 Strong Execution for more Innovation Evotec AG, H1 2014 Interim Report, 12 August 2014 Forward-looking statements Information set forth in this presentation contains forward-looking statements,
More informationIn the last decade, there have been major changes in the
233 Promising New Treatments for Rheumatoid Arthritis The Kinase Inhibitors Yusuf Yazici, M.D., and Alexandra L. Regens, B.A. Abstract Three major advances over the last decade have impacted the way we
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 203: Tocilizumab (subcutaneous) in combination with methotrexate or as monotherapy for the treatment
More informationAn Introduction to Valuations
An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your
More informationusing the fully human ADLib system
Company Research and Analysis Report FISCO Ltd. http://www.fisco.co.jp 伪 伪 Focusing on improving technology to obtain antibodies using the fully human ADLib system (4583) (subsequently, the company ) is
More informationXENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14
XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code
More informationIMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282
IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris
More informationSanthera Reports Successful 2006
Published: 07:00 02.03.2007 GMT+1 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Santhera Reports Successful 2006 Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty
More informationCorporate Presentation. October 2015
Corporate Presentation October 2015 Forward-looking Statements Certain statements contained herein including, but not limited to, expected licensing transactions, statements related to anticipated timing
More informationSummary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)
EMA/662624/2015 Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) This is a summary of the risk management plan (RMP) for Orkambi, which details the measures to be taken
More informationCore therapeutic areas
Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014
More informationDeutsches Eigenkapitalforum. Frankfurt November 22, 2011
Deutsches Eigenkapitalforum Frankfurt November 22, 2011 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking
More informationForward step pby step with Action Plan 2016
Forward step pby step with Action Plan 2016 Evotec AG, Full-Year Results 2012, Frankfurt/Main, 26 March 2013 Forward-looking statements Information set forth in this presentation contains forward-looking
More information